Industry Discussion: Building a World-Class Innovative Biologics Industry in China

  • Recommend
  • Tweet
  • Print
  • Email

Wednesday, October 24, 4:30-5:30pm

The R&D based Pharmaceutical Association Committee (RDPAC) and BIO have commissioned a study with the support of the Boston Consulting Group (BCG) to assess multiple policy levers which have the potential to accelerate the development of the therapeutic biologics sector in China and the integration of the Chinese therapeutic biologics industry into global R&D and healthcare markets. The therapeutic biologics industry holds significant promise for China to achieve breakthrough innovation and to address largely unmet medical needs in diseases such as diabetes, cancer, and immunological impairment. As biotechnology has been designated as one of China’s seven strategic emerging industries by the government in the current 12th five-year plan, this study is in the process of formulating a set of recommendations which balance the immediate next steps for the industry with long-term action plans.

Moderator:

  • Joseph Damond, Senior Vice President, International Affairs, BIO

Panelists:

  • James Cai, Medical Director of Shanghai Roche Pharmaceutical Co.
  • Joseph Cho, Managing Director, RDPAC
  • Shi Luwen, PhD, Professor, Peking University School of Pharmaceutical Sciences
  • Yu Mingde, President, China Pharmaceutical Enterprises Association

Who's Who

Joseph Damond
Senior Vice President, International Affairs, BIO

As Senior Vice President for International Affairs at the Biotechnology Industry Organization (BIO), Mr. Damond is responsible for developing and implementing the industry association’s program of international advocacy and outreach, including the areas of trade policy and foreign government relations.

Prior to taking his position at BIO, Mr. Damond was Vice President for International Government Relations in Pfizer’s Washington Office from 2006-2011. In that capacity he was responsible for managing and coordinating Pfizer’s international trade issues with the Administration and Congress.

Prior to his appointment at Pfizer in 2006, Mr. Damond was with the Pharmaceutical Research and Manufacturers of America (PhRMA) for five years.  As PhRMA’s Deputy Vice President for International Affairs, he was responsible for managing PhRMA’s programs with respect to market access barriers that affect the research-based pharmaceutical industry, as well as managing PhRMA’s Asia and Japan programs.

Before coming to PhRMA, Mr. Damond spent 12 years as a trade negotiator at the Office of the United States Trade Representative, where his last assignment, from 1999-2001, was as Deputy Assistant U.S. Trade Representative for Asia and Pacific/APEC Affairs.  During this time, he was also chief negotiator of the historic U.S.-Vietnam Bilateral Trade agreement, completed in July 2000.  Prior to his time at USTR, Mr. Damond also spent four years at the U.S. Commerce Department, working on bilateral and multilateral trade negotiations.

Mr. Damond received his Master’s degree from Princeton University’s Woodrow Wilson School of Public and International Affairs in 1985, and his undergraduate degree magna cum laude from Georgetown University, School of Foreign Service, in 1983.